EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:EPRX - CA29842P1053 - Common Stock
EPRX.CA Key Statistics, Chart & Performance
The current stock price of EPRX.CA is 12.5 CAD. In the past month the price increased by 43.33%. In the past year, price increased by 186.67%.
EPRX.CA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to EPRX.CA. When comparing the yearly performance of all stocks, EPRX.CA is one of the better performing stocks in the market, outperforming 90.24% of all stocks.
EPRX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EPRX.CA. While EPRX.CA has a great health rating, there are worries on its profitability.
EPRX.CA Financial Highlights
Over the last trailing twelve months EPRX.CA reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS decreased by -6.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.81% | ||
| ROE | -32.63% | ||
| Debt/Equity | 0 |
EPRX.CA Forecast & Estimates
8 analysts have analysed EPRX.CA and the average price target is 14.96 CAD. This implies a price increase of 19.71% is expected in the next year compared to the current price of 12.5.
EPRX.CA Ownership
EPRX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 381.69M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 159.63M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 76.74M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 23.57 | 45.57M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 30.58M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 27.30M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.96M | ||
| MPH.CA | MEDICURE INC | N/A | 13.78M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 10.96M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.48M | ||
| KNE.CA | KANE BIOTECH INC | N/A | 7.53M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 6.77M |
Related stock screener links
About EPRX.CA
Company Profile
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Company Info
EUPRAXIA PHARMACEUTICALS INC
201-2067 Cadboro Bay Rd.
Victoria BRITISH COLUMBIA CA
CEO: James A. Helliwell
Employees: 33
Phone: 12505903968
EUPRAXIA PHARMACEUTICALS INC / EPRX.CA FAQ
Can you describe the business of EUPRAXIA PHARMACEUTICALS INC?
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
What is the current price of EPRX stock?
The current stock price of EPRX.CA is 12.5 CAD. The price increased by 4.25% in the last trading session.
What is the dividend status of EUPRAXIA PHARMACEUTICALS INC?
EPRX.CA does not pay a dividend.
What is the ChartMill rating of EUPRAXIA PHARMACEUTICALS INC stock?
EPRX.CA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does EUPRAXIA PHARMACEUTICALS INC belong to?
EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) operates in the Health Care sector and the Biotechnology industry.
Would investing in EUPRAXIA PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EPRX.CA.